Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The publication presents a phase II clinical trial evaluating the efficacy and safety of a novel targeted therapy in patients with advanced non-small cell lung cancer harboring specific genetic mutations.
The study demonstrates:
- Meaningful improvement in progression-free survival
- Manageable safety profile
These results suggest that this therapy may be a promising treatment option for this patient population.
Further research in larger, randomized trials is warranted to confirm these findings.